The Corporate Venture arm of a Hi-Tech Company current manages a total of $850 million in assets, and is looking to make equity investments ranging from $2-$5 million with the ability to allocate up to $10 million generally in series A-C rounds. The majority of fund’s investment have been throughout the United States although they have and are willing to invest internationally as well. The fund is actively reviewing new opportunities can could make 3-4 investments over the next year.

The Fund is currently interested in sectors of Medical Devices, Diagnostics and Healthcare IT that increase connectivity in the healthcare ecosystem. The fund is particularly interest in verticals of Health and Wellness, Chronic Disease Care, Aging in Place, Telemedicine, Genomics, Patient Monitoring, Clinical Trails Management, Mobile Software Healthcare IT Applications, and Electronic Medical Records Management. The fund is willing to invest in devices with 510k pathways however the fund is not currently considering highly invasive medical devices.

The Fund is looking for privately held companies with experienced management teams. The fund generally looks to take a board or observer seat following investment and is willing to both lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A European VC firm has recently closed €75 million and is looking to make its first allocations. The firm is looking to invest in Europe and North America, and typically allocates about €5 million equity to each portfolio company, generally over several tranches. The firm has no set number of allocations that it plans to make over the next 6-9 months but they are actively seeking new opportunities.

The firm invests in therapeutics to treat rare diseases. The firm is agnostic regarding technology type and indication areas pending the targeted market can have expedited regulatory approval through a rare/orphan status. The fund typically invests early but is open to companies with assets ranging from preclinical development through Phase II.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital company founded in 1995 and based in Northern Europe manages approximately €200 in assets, with 2 life science investment funds. The firm makes equity investments into early stage companies of up to €2 million initially and €8-€10 million of the lifetime of the investment. The firm is currently looking for companies located throughout Europe and the US and plans to make approximately 2 investments over the next 6-9 months.

The firm is looking for companies in areas of Therapeutics, Diagnostics, Medical Devices and Biotech Other. For Therapeutics and Diagnostics the firm is looking for companies with platform technologies that are anywhere from 12-36 months pre proof of concept in animal trials. Subsectors of particular interest in this areas include Immunology, Anti-Infectives, Vaccines, Ophthalmology, Orphan Indications, and Biomarkers. In areas of Medical devices the firm looks for companies around 12 months pre-proof of concept and is particularly interested in biomaterials, surface treatments, therapeutic devices, biofilms, coatings, remote patient monitoring and assisted living. In the Biotech Other space, the firm is interested in early stage companies in sectors of Agbio, Industrial Bio, Cleantech, and Nutrition. The firm is also interested in companies that are developing better methods for biosynthesis for biologics. The firm is also interested in Healthcare IT opportunities including Apps, Sensors, Databases and Systems.

 The firm values the company’s technology as it’s 1^st priority. The firm is looking for companies with platform technologies that are looking to stay a development company and build a strong pipeline of potential candidates. The firm is willing to help companies complete their management teams and looks to secure a seat on the company’s board following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a multinational conglomerate corporation seeks to invest in disruptive early stage technologies and business model innovations. The firm looks to invest in six areas including the life science space that are strategically relevant its parent company. The firm prefers to invest in Series B round or later, but it is open to consider seed and Series A round. The firm generally allocates approximately $2 million -$5 million for early-stage companies, on a case-by-case basis. Investments are typically in forms of equity, whereas other capital structures may also be considered. The firm is seeking new investment opportunities around the globe with a focus on United States, Europe, Brazil, Singapore and China.

The firm is currently looking for new opportunities in Medical Technology, Diagnostics, Specific biotech areas and Healthcare IT. In the Medtech sector, the firm is interested in companies developing Class II Medical devices with 510(K) regulatory pathways preferably in clinic. The firm focuses on companies developing dental devices, would care, coatings and diagnostic devices. In the Biotech sector, the firm focuses on companies targeting infection prevention and food safety (such as testing and hygiene monitoring products). The firm is also interested in Healthcare IT companies developing software, solutions and platforms for better clinical and financial performance.

The firm focuses on investments in private companies. The firm considers pre-revenue companies with strong and experienced management team. The firm will take a board seat occasionally, depending on the investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A hedge fund with multiple European Offices is looking to invest in growth, expansion and roll-out stage companies, primarily in Series D-E rounds, and sometimes in Series C rounds. Initial investments are typically $8-10 million. The firm is generally focused on Western Europe but is also open to opportunities in North America.

The firm’s primary investment themes are personalized medicine and agriculture. Within personalized medicine, the firm focus subsector is molecular diagnostics, but other areas of diagnostics technology may be of interest; however the firm is typically not interested in patient monitoring technologies or care management. The firm has also invested in medical devices, but is only interested in devices that are highly disruptive or which represent completely new markets. The firm will consider any indication but is particularly interested in oncology and neurology. The firm only invests in life science companies that have products which have attained approval or which are very close to approval and have significant amounts of data. 

The firm prefers to invest in companies at the early commercialization stage that have completed development of a technology but require capital to expand sales and marketing efforts. The firm is also open to early growth investments in companies with existing revenues. The firm is currently focused on investing in privately held companies but will also consider investing in publicly traded companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A VC fund with offices in the US and Asia manages roughly $70 million that it is actively seeking to invest. The initial investment size is highly variable though the firm is looking to provide up to $10+ million over the lifetime of the investment. The firm generally provides capital in the form of equity though they also have experience in working with convertible notes. The firm is interested in companies located either in the US or Asia. The firm’s primary focus is on private companies while public investments are also made selectively.

The fund is currently interested in companies developing Therapeutics, Diagnostics, Medical Devices, Healthcare IT, and R&D Services Companies. The firm is entirely opportunistic in terms of subsector and indication. In terms of phase of development, the firm is looking for companies with lead assets in the preclinical stage to companies that already have products on the market. The firm will consider companies in various stages on a case by case basis including seed financing.

The fund views the management team as one of the most important variables in selecting a potential investment. The firm looks for highly experienced and trustworthy management teams. The firm is highly interested in US based companies that are looking to expand into Asian markets or vice versa as member of the fund can add much value in these situations with their vast Asian network. However this US-Asia business development angle is not a criteria or requirement for the firm’s investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A pharmaceutical development company seeks to acquire assets in the therapeutics sector, and form new companies to develop these assets to commercialization. The firm primarily works with biotech companies based in North America.

The firm is interested in a broad range of therapeutic assets that have some level of proof of concept data (preferably in humans); the firm’s primary area of expertise is dermatology, and assets in the inflammation and oncology sectors are also highly of interest (but not immuno-oncology). In general the firm does not invest in infectious diseases, diseases of the nervous system, mental and behavioral disorders, or disease areas that require large trial sizes such as cardiovascular disease and diabetes.

When the firm acquires an asset, the firm typically keeps on the key team members associated with that asset and works with them throughout the development process.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com